JP2019533019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533019A5 JP2019533019A5 JP2019542355A JP2019542355A JP2019533019A5 JP 2019533019 A5 JP2019533019 A5 JP 2019533019A5 JP 2019542355 A JP2019542355 A JP 2019542355A JP 2019542355 A JP2019542355 A JP 2019542355A JP 2019533019 A5 JP2019533019 A5 JP 2019533019A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- subject
- compound
- dose
- biomarker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 49
- 229940126062 Compound A Drugs 0.000 claims 17
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 17
- 239000000090 biomarker Substances 0.000 claims 12
- 150000002632 lipids Chemical class 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 239000012472 biological sample Substances 0.000 claims 7
- 239000002207 metabolite Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 108010078791 Carrier Proteins Proteins 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 4
- 230000002068 genetic effect Effects 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 108010023302 HDL Cholesterol Proteins 0.000 claims 3
- 210000001685 thyroid gland Anatomy 0.000 claims 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 3
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 2
- 101710095342 Apolipoprotein B Proteins 0.000 claims 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims 2
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 claims 2
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 claims 2
- 108010028554 LDL Cholesterol Proteins 0.000 claims 2
- 102100032251 Pro-thyrotropin-releasing hormone Human genes 0.000 claims 2
- 102000011923 Thyrotropin Human genes 0.000 claims 2
- 108010061174 Thyrotropin Proteins 0.000 claims 2
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 claims 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 claims 2
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 claims 2
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 229960000874 thyrotropin Drugs 0.000 claims 2
- 230000001748 thyrotropin Effects 0.000 claims 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 claims 2
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 claims 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims 1
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 claims 1
- 102100028162 ATP-binding cassette sub-family C member 3 Human genes 0.000 claims 1
- 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 claims 1
- 102100028186 ATP-binding cassette sub-family C member 5 Human genes 0.000 claims 1
- 102100028282 Bile salt export pump Human genes 0.000 claims 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101000986633 Homo sapiens ATP-binding cassette sub-family C member 3 Proteins 0.000 claims 1
- 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 claims 1
- 101000986622 Homo sapiens ATP-binding cassette sub-family C member 5 Proteins 0.000 claims 1
- 101000969812 Homo sapiens Multidrug resistance-associated protein 1 Proteins 0.000 claims 1
- 101600111816 Homo sapiens Sex hormone-binding globulin (isoform 1) Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 claims 1
- 102100032877 Multidrug and toxin extrusion protein 1 Human genes 0.000 claims 1
- 102100032858 Multidrug and toxin extrusion protein 2 Human genes 0.000 claims 1
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 claims 1
- 108091006744 SLC22A1 Proteins 0.000 claims 1
- 108091006754 SLC22A11 Proteins 0.000 claims 1
- 108091006735 SLC22A2 Proteins 0.000 claims 1
- 108091006734 SLC22A3 Proteins 0.000 claims 1
- 108091006739 SLC22A6 Proteins 0.000 claims 1
- 108091006741 SLC22A8 Proteins 0.000 claims 1
- 108091007574 SLC47A1 Proteins 0.000 claims 1
- 108091007575 SLC47A2 Proteins 0.000 claims 1
- 108091006731 SLCO1B1 Proteins 0.000 claims 1
- 108091006730 SLCO1B3 Proteins 0.000 claims 1
- 108091006686 SLCO2B1 Proteins 0.000 claims 1
- 102300044179 Sex hormone-binding globulin isoform 1 Human genes 0.000 claims 1
- 102100032416 Solute carrier family 22 member 1 Human genes 0.000 claims 1
- 102100021493 Solute carrier family 22 member 11 Human genes 0.000 claims 1
- 102100032417 Solute carrier family 22 member 2 Human genes 0.000 claims 1
- 102100036929 Solute carrier family 22 member 3 Human genes 0.000 claims 1
- 102100036930 Solute carrier family 22 member 6 Human genes 0.000 claims 1
- 102100035227 Solute carrier family 22 member 8 Human genes 0.000 claims 1
- 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 claims 1
- 102100027239 Solute carrier organic anion transporter family member 1B3 Human genes 0.000 claims 1
- 102100027264 Solute carrier organic anion transporter family member 2B1 Human genes 0.000 claims 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229940034208 thyroxine Drugs 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 229940035722 triiodothyronine Drugs 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023157999A JP2024001055A (ja) | 2016-10-18 | 2023-09-22 | Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法 |
| JP2025079296A JP2025122012A (ja) | 2016-10-18 | 2025-05-12 | Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409833P | 2016-10-18 | 2016-10-18 | |
| US62/409,833 | 2016-10-18 | ||
| US201762516594P | 2017-06-07 | 2017-06-07 | |
| US62/516,594 | 2017-06-07 | ||
| PCT/US2017/057203 WO2018075650A1 (en) | 2016-10-18 | 2017-10-18 | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023157999A Division JP2024001055A (ja) | 2016-10-18 | 2023-09-22 | Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533019A JP2019533019A (ja) | 2019-11-14 |
| JP2019533019A5 true JP2019533019A5 (https=) | 2020-11-19 |
Family
ID=60480362
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542355A Pending JP2019533019A (ja) | 2016-10-18 | 2017-10-18 | Ｔｈｒ−ベータアゴニストで肝臓障害又は脂質障害を治療する方法 |
| JP2023157999A Pending JP2024001055A (ja) | 2016-10-18 | 2023-09-22 | Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法 |
| JP2025079296A Pending JP2025122012A (ja) | 2016-10-18 | 2025-05-12 | Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023157999A Pending JP2024001055A (ja) | 2016-10-18 | 2023-09-22 | Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法 |
| JP2025079296A Pending JP2025122012A (ja) | 2016-10-18 | 2025-05-12 | Ｔｈｒ－ベータアゴニストで肝臓障害又は脂質障害を治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11090308B2 (https=) |
| EP (2) | EP3528817B1 (https=) |
| JP (3) | JP2019533019A (https=) |
| KR (2) | KR20230156159A (https=) |
| CN (1) | CN110167557A (https=) |
| AU (1) | AU2017346871B2 (https=) |
| CA (1) | CA3040888A1 (https=) |
| DK (1) | DK3528817T3 (https=) |
| ES (1) | ES2924257T3 (https=) |
| IL (2) | IL302336B2 (https=) |
| MX (1) | MX394463B (https=) |
| WO (1) | WO2018075650A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| SI4122464T1 (sl) | 2017-03-28 | 2024-07-31 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| CN110627773B (zh) * | 2018-06-22 | 2021-03-19 | 海创药业股份有限公司 | 氘代mgl-3196化合物及其用途 |
| AR115666A1 (es) * | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
| CA3111025C (en) * | 2018-09-06 | 2023-10-31 | Galmed Research And Development Ltd | Combination therapy for the treatment of liver disease |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN111320609A (zh) * | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| PT3911647T (pt) * | 2019-01-15 | 2024-03-04 | Gilead Sciences Inc | Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| CN113474335B (zh) * | 2019-02-21 | 2024-12-03 | 南京瑞捷医药科技有限公司 | 化合物及其作为甲状腺激素受体激动剂的用途 |
| KR20220017917A (ko) | 2019-05-08 | 2022-02-14 | 알리고스 테라퓨틱스 인코포레이티드 | Thr-베타의 조절제 및 이의 사용 방법 |
| AU2020336272A1 (en) * | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) * | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| WO2021104288A1 (zh) * | 2019-11-26 | 2021-06-03 | 昆药集团股份有限公司 | 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用 |
| CN111562321B (zh) * | 2020-04-16 | 2022-10-28 | 广东省结核病控制中心 | 用于检测活动性肺结核的粪便代谢物及其检测系统 |
| WO2022052822A1 (zh) * | 2020-09-10 | 2022-03-17 | 苏州科睿思制药有限公司 | Resmetirom的晶型及其制备方法和用途 |
| EP4204419A1 (en) | 2020-10-19 | 2023-07-05 | Teva Pharmaceuticals International GmbH | Solid state forms of resmetirom |
| KR20230142523A (ko) * | 2021-02-01 | 2023-10-11 | 마드리갈 파마슈티칼스, 인크. | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 |
| US20250000836A1 (en) * | 2021-07-21 | 2025-01-02 | Cyta Therapeutics, Inc. | Particle delivery of thyroid hormone receptor agonists and antagonists |
| PE20241327A1 (es) * | 2021-11-11 | 2024-06-26 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-beta |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2024263714A1 (en) * | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| WO2025083699A2 (en) | 2023-10-16 | 2025-04-24 | Cipla Limited | Resmetirom polymorphs and process thereof |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025245216A1 (en) * | 2024-05-22 | 2025-11-27 | Terns Pharmaceuticals, Inc. | Treatment of liver disorders with a thr-beta agonist |
| WO2026074443A1 (en) | 2024-10-01 | 2026-04-09 | Assia Chemical Industries Ltd. | Solid state forms of resmetirom |
| CN121648128A (zh) * | 2026-02-03 | 2026-03-13 | 华中科技大学同济医学院附属同济医院 | 特拉唑嗪或其药学上可接受的盐在制备用于预防和/或治疗肝纤维化的药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5615272A (en) | 1979-07-17 | 1981-02-14 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| CN100469769C (zh) | 2003-03-24 | 2009-03-18 | 弗·哈夫曼-拉罗切有限公司 | 作为逆转录酶抑制剂的苄基-哒嗪酮 |
| ITRM20030363A1 (it) | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| US20080152700A1 (en) | 2004-06-01 | 2008-06-26 | Reza Sheikhnejad | Methods and compositions for the inhibition of gene expression |
| US7807647B2 (en) | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
| DK1919878T3 (da) | 2005-07-21 | 2010-10-25 | Hoffmann La Roche | Pyridazinonderivater som thyroidhormonreceptoragonister |
| HRP20100611T1 (hr) | 2007-06-06 | 2010-12-31 | Torrent Pharmaceuticals Ltd | Novi spojevi |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| US8858502B2 (en) | 2012-10-10 | 2014-10-14 | Alcon Research, Ltd. | Systems and methods for external pressure sensing |
| CN106132969A (zh) * | 2014-02-14 | 2016-11-16 | 森普拉制药公司 | 用于治疗糖尿病和肝病的组合物和方法 |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| AR115666A1 (es) | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
-
2017
- 2017-10-18 WO PCT/US2017/057203 patent/WO2018075650A1/en not_active Ceased
- 2017-10-18 JP JP2019542355A patent/JP2019533019A/ja active Pending
- 2017-10-18 EP EP17804979.7A patent/EP3528817B1/en active Active
- 2017-10-18 IL IL302336A patent/IL302336B2/en unknown
- 2017-10-18 MX MX2019004492A patent/MX394463B/es unknown
- 2017-10-18 US US16/343,065 patent/US11090308B2/en active Active
- 2017-10-18 EP EP22175048.2A patent/EP4112056B1/en active Active
- 2017-10-18 IL IL266054A patent/IL266054B2/en unknown
- 2017-10-18 KR KR1020237037485A patent/KR20230156159A/ko active Pending
- 2017-10-18 CA CA3040888A patent/CA3040888A1/en active Pending
- 2017-10-18 AU AU2017346871A patent/AU2017346871B2/en active Active
- 2017-10-18 CN CN201780078133.2A patent/CN110167557A/zh active Pending
- 2017-10-18 KR KR1020197014495A patent/KR20190109387A/ko not_active Ceased
- 2017-10-18 ES ES17804979T patent/ES2924257T3/es active Active
- 2017-10-18 DK DK17804979.7T patent/DK3528817T3/da active
-
2021
- 2021-07-07 US US17/369,197 patent/US11806353B2/en active Active
-
2023
- 2023-09-21 US US18/371,229 patent/US20240156826A1/en not_active Abandoned
- 2023-09-22 JP JP2023157999A patent/JP2024001055A/ja active Pending
-
2025
- 2025-05-12 JP JP2025079296A patent/JP2025122012A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533019A5 (https=) | ||
| US11806353B2 (en) | Methods of treating liver disorders or lipid disorders with a THR-beta agonist | |
| Flanagan et al. | Activation of 5-HT2 receptors reduces inflammation in vascular tissue and cholesterol levels in high-fat diet-fed apolipoprotein E knockout mice | |
| Tosco et al. | A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR | |
| Zhou et al. | Adipose‐specific lipin‐1 overexpression renders hepatic ferroptosis and exacerbates alcoholic steatohepatitis in mice | |
| Ni et al. | USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638 | |
| Zhang et al. | STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma | |
| Hwangbo et al. | Prevalence and clinical characteristics of recently diagnosed type 2 diabetes patients with positive anti-glutamic acid decarboxylase antibody | |
| Braunstein et al. | A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons | |
| US20130276513A1 (en) | Methods for diagnosing and assessing kidney disease | |
| Ellis et al. | Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism | |
| Støy et al. | Low interleukin-22 binding protein is associated with high mortality in alcoholic hepatitis and modulates interleukin-22 receptor expression | |
| Cao et al. | ABCC2 c.-24 C> T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects | |
| Li et al. | Ube2L6 promotes M1 macrophage polarization in high-fat diet-fed obese mice via ISGylation of STAT1 to trigger STAT1 activation | |
| JP2013545759A (ja) | 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択 | |
| Xu et al. | Cranial irradiation induces hypothalamic injury and late-onset metabolic disturbances in juvenile female rats | |
| Han et al. | Circulating glutamine/glutamate ratio is closely associated with type 2 diabetes and its associated complications | |
| Dagli-Hernandez et al. | Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: a case report | |
| Vinagre et al. | Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature | |
| CN118252935A (zh) | Trafd1抑制剂在制备治疗和/或预防hbv-ra药物中的应用 | |
| Zhang et al. | IL-17 enhanced the susceptibility to fluoxetine resistance in depression via the JAK1-STAT6 signaling pathway | |
| Al‐Bataineh et al. | Tumor necrosis factor alpha increases P‐glycoprotein expression in a BME‐UV in vitro model of mammary epithelial cells | |
| Takahashi et al. | Association of the TNF-α-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects | |
| John et al. | Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations | |
| Potaczek et al. | The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects |